HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: P600009-JLR200v1 47/12/2820    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Clarenbach, J. J. Articles by Sudhop, T. Search for Related Content PubMed PubMed Citation Articles by Clarenbach, J. J. Articles by Sudhop, T. Social Bookmarking                      What's this?

Journal of Lipid Research, Vol. 47, 2820-2824, December 2006
Copyright © 2006 by American Society for Biochemistry and Molecular Biology

Patient-Oriented Research

The lipid-lowering effect of ezetimibe in pure vegetarians

Jacob J. Clarenbach¹, Michael Reber¹, Dieter Lütjohann, Klaus von Bergmann and Thomas Sudhop²

Department of Clinical Pharmacology, University of Bonn, Bonn, Germany

Published, JLR Papers in Press, September 11, 2006.

¹ J. J. Clarenbach and M. Reber contributed equally to this work.

² To whom correspondence should be addressed. e-mail: sudhop{at}bfarm.de

ABSTRACT

Results of previous studies have shown that ezetimibe (10 mg/day) reduces LDL cholesterol in patients with mild hypercholesterolemia on a normal-cholesterol diet (dietary intake of 200–500 mg/day) by 16–22%. However, the LDL cholesterol-lowering effect of ezetimibe in subjects with an extremely low dietary cholesterol intake (vegetarians) has not been studied. We conducted a randomized, double-blind, placebo-controlled, two-phase crossover study in 18 healthy pure vegetarians to assess the effect of ezetimibe (10 mg/day) on plasma lipids, cholesterol absorption, and its synthesis. Treatment periods lasted 2 weeks each, with an intervening 2 week washout period. Fractional cholesterol absorption was determined using the continuous dual stable isotope feeding method. Mean dietary cholesterol intake in the pure vegetarians was extremely low and averaged 29.4 ± 16.8 and 31.4 ± 14.4 mg/day during the placebo and ezetimibe administration phases, respectively. Fractional cholesterol absorption during the placebo phase was 48.2 ± 8.2% and was decreased by 58% during ezetimibe treatment to 20.2 ± 6.2% (P < 0.001). This change in intestinal cholesterol absorption was followed by a significant reduction in LDL cholesterol of 17.3%. In individuals with extremely low dietary cholesterol intake, treatment with ezetimibe (10 mg/day) leads to a significant reduction of cholesterol absorption and a clinically relevant decrease of plasma LDL cholesterol, comparable to that of subjects with a normal dietary cholesterol intake. Thus, the lipid-lowering effect of ezetimibe is mediated mainly through a reduction of the absorption of endogenous (biliary) cholesterol.

Supplementary key words cholesterol absorption • cholesterol synthesis • campesterol • sitosterol • lathosterol

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				B. Hansel, C. Nicolle, F. Lalanne, F. Tondu, T. Lassel, Y. Donazzolo, J. Ferrieres, M. Krempf, J.-L. Schlienger, B. Verges, et al. Effect of low-fat, fermented milk enriched with plant sterols on serum lipid profile and oxidative stress in moderate hypercholesterolemia Am. J. Clinical Nutrition, September 1, 2007; 86(3): 790 - 796. [Abstract] [Full Text] [PDF]